Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans
The Army spent decades dosing enlisted men with psychedelics they weren't told they were taking. Eighty years later, the VA and Pentagon are running versions of the same experiment again — with consent forms, IRBs, and an executive order behind them.
LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
A company-by-company look at the smallest patent footprint of any compound on our tracker — and why Definium, the company furthest along in trials, barely shows up in it.
The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
A company-by-company look at who holds 5-MeO-DMT''s 164 patents — and why the program with the strongest Phase 2b data in the field has almost none of them.
Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
A company-by-company look at who's patenting psilocybin, what they're actually claiming, and why one of the biggest names in the field has spent a year fighting to keep its patents alive.
677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
Our own count of who's filing patents on psilocybin, MDMA, LSD, ketamine, ibogaine, and 5-MeO-DMT — what they're claiming to treat, where they're based, and the one company that's already been told no by the FDA.
Clinical vs. Consumer: Navigating the New Psilocybin Landscape
The same compound, very different experiences. Understanding the difference between clinical and consumer use is essential.